Emerging retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is creating considerable excitement within the healthcare community. Early clinical studies have demonstrated impressive decreases in overall mass and gains in metabolic markers for patients with obesity . Scientists believe this novel approach could represent a si